Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
Related Research units
Abstract
The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome in patients receiving cetuximab plus FOLFOX-4 (oxaliplatin/5-fluorouracil/folinic acid) as first-line therapy for metastatic colorectal cancer (mCRC).
Bibliographical data
| Original language | English |
|---|---|
| Article number | 7 |
| ISSN | 0923-7534 |
| Publication status | Published - 2011 |
| pubmed | 21228335 |
|---|
